Excellergy is a biotechnology company focused on developing a pioneering portfolio of trifunctional effector cell response inhibitors (ECRIs) to address severe allergic diseases. By utilizing clinically validated Immunoglobulin E (IgE) biology and innovative ECRI pharmacology, Excellergy aims to surpass traditional anti-IgE therapies by directly targeting the source of allergic signaling—IgE bound to effector cells. Headquartered in Palo Alto, California, the company is committed to advancing the standard of care in allergy treatment and improving patient quality of life.
Leadership & Board
Current Number of Employees26
Current LinkedIn Followers481
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$70M
Total Amount Raised$70M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$70M
Latest Funding Amount$70M
Latest Funding RoundSeries A
Latest Funding RoundSeries A
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
Excellergy had 26 employees as of September 14, 2026. The number of employees increased by 0 (0.00%) week-over-week.
26Latest Employee Count
0(0.00%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
Excellergy had 481 followers as of September 14, 2026. The number of followers increased by 0 (0.00%) week-over-week.
481Latest Followers Count
0(0.00%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.